274 related articles for article (PubMed ID: 20951177)
1. The therapeutic equivalence of complex drugs.
Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
[TBL] [Abstract][Full Text] [Related]
2. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
3. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
4. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
5. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
6. Assessing the bioequivalence of biosimilars The Retacrit case.
Schellekens H
Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
[TBL] [Abstract][Full Text] [Related]
7. Generic immunosuppression in solid organ transplantation: a Canadian perspective.
Harrison JJ; Schiff JR; Coursol CJ; Daley CJ; Dipchand AI; Heywood NM; Keough-Ryan TM; Keown PA; Levy GA; Lien DC; Wichart JR; Cantarovich M
Transplantation; 2012 Apr; 93(7):657-65. PubMed ID: 22267158
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars: how similar or dissimilar are they?
Roger SD
Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
Walenga JM; Jackson CM; Kessler CM
Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
[TBL] [Abstract][Full Text] [Related]
10. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.
Meredith PA
Curr Med Res Opin; 2009 Sep; 25(9):2179-89. PubMed ID: 19601710
[TBL] [Abstract][Full Text] [Related]
11. Current regulatory approaches of bioequivalence testing.
Karalis V; Macheras P
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence and narrow therapeutic index drugs.
Benet LZ; Goyan JE
Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar medicines--new challenges for a new class of medicine.
Fox A
J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
[TBL] [Abstract][Full Text] [Related]
14. Statistical assessment of biosimilar products.
Chow SC; Liu JP
J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars: it's not as simple as cost alone.
Roger SD; Goldsmith D
J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle iron medicinal products - Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies.
Borchard G; Flühmann B; Mühlebach S
Regul Toxicol Pharmacol; 2012 Nov; 64(2):324-8. PubMed ID: 22951348
[TBL] [Abstract][Full Text] [Related]
17. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
18. Development of generic low molecular weight heparins: a perspective.
Fareed J; Leong W; Hoppensteadt DA; Jeske WP; Walenga J; Bick RL
Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
[TBL] [Abstract][Full Text] [Related]
19. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
Brodniewicz-Proba T
Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
[TBL] [Abstract][Full Text] [Related]
20. Statistical Considerations in the Design of Biosimilar Cancer Clinical Trials.
Ahn C; Lee SC
Ungyong Tonggye Yongu; 2011 Jun; 24(3):495-503. PubMed ID: 23805045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
